Rxwire
In the news · 48h FDA 38 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AstraZeneca 3 AbbVie 2 Daiichi Sankyo 2
Approvals & regulatory · first seen yesterday, updated yesterday

Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod

2 outlets Roche FDA

A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.

Summary from BioSpace - All News.

Coverage 2 articles · 2 outlets

  1. BioSpace - All News
    Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
  2. BioPharma Dive
    Roche, Ionis RNA drug scores in kidney disease study